Integrated clinical experience with ONC201 in H3 K27M glioma.

Andrew S. Chi; Sharon L. Gardner; Isabel Arrillaga; Patrick Y. Wen; Tracy Batchelor; Matthew David Hall; Yazmin Odia; Wafik Tharwat Zaky; Soumen Khatua; Nicole A. Shonka; Ziad Khatib; Rohinton Tarapore; Lee Schalop; Joshua E. Allen; Wolfgang Oster; Minesh P. Mehta

doi:10.1200/JCO.2018.36.15_suppl.2059

Integrated clinical experience with ONC201 in H3 K27M glioma.

Andrew S. Chi, Sharon L. Gardner, Isabel Arrillaga, Patrick Y. Wen, Tracy Batchelor, Matthew David Hall, Yazmin Odia, Wafik Tharwat Zaky, Soumen Khatua, Nicole A. Shonka, Ziad Khatib, Rohinton Tarapore, Lee Schalop, Joshua E. Allen, Wolfgang Oster, Minesh P. Mehta

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	36
DOIs	https://doi.org/10.1200/JCO.2018.36.15_suppl.2059
State	Published - May 20 2018

Disciplines

Medicine and Health Sciences
Pathology
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2018.36.15_suppl.2059License: Unspecified

Cite this

@article{79c33a896de9463aaaf94ff575d788f6,

title = "Integrated clinical experience with ONC201 in H3 K27M glioma.",

author = "Chi, {Andrew S.} and Gardner, {Sharon L.} and Isabel Arrillaga and Wen, {Patrick Y.} and Tracy Batchelor and Hall, {Matthew David} and Yazmin Odia and Zaky, {Wafik Tharwat} and Soumen Khatua and Shonka, {Nicole A.} and Ziad Khatib and Rohinton Tarapore and Lee Schalop and Allen, {Joshua E.} and Wolfgang Oster and Mehta, {Minesh P.}",

note = "2059 Background: ONC201 is a DRD2 antagonist in Phase II trials for cancers that exhibit dysregulation of the dopamine pathway. We previously reported an objective response in the first recurrent H3 K27M midline glioma patient who received ONC201 and that H3 K27M gliomas exhibit enhanced sensitivity to the compound in vitro.",

year = "2018",

month = may,

day = "20",

doi = "10.1200/JCO.2018.36.15_suppl.2059",

language = "American English",

volume = "36",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Integrated clinical experience with ONC201 in H3 K27M glioma.

AU - Chi, Andrew S.

AU - Gardner, Sharon L.

AU - Arrillaga, Isabel

AU - Wen, Patrick Y.

AU - Batchelor, Tracy

AU - Hall, Matthew David

AU - Odia, Yazmin

AU - Zaky, Wafik Tharwat

AU - Khatua, Soumen

AU - Shonka, Nicole A.

AU - Khatib, Ziad

AU - Tarapore, Rohinton

AU - Schalop, Lee

AU - Allen, Joshua E.

AU - Oster, Wolfgang

AU - Mehta, Minesh P.

N1 - 2059 Background: ONC201 is a DRD2 antagonist in Phase II trials for cancers that exhibit dysregulation of the dopamine pathway. We previously reported an objective response in the first recurrent H3 K27M midline glioma patient who received ONC201 and that H3 K27M gliomas exhibit enhanced sensitivity to the compound in vitro.

PY - 2018/5/20

Y1 - 2018/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2059

U2 - 10.1200/JCO.2018.36.15_suppl.2059

DO - 10.1200/JCO.2018.36.15_suppl.2059

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Integrated clinical experience with ONC201 in H3 K27M glioma.

Disciplines

Access to Document

Other files and links

Cite this